Salivary micro RNAs as biomarkers for oropharyngeal cancer.

Autor: Ekanayake Weeramange C; Saliva and Liquid Biopsy Translational Laboratory, Griffith Institute for Drug Discovery (GRIDD) and Menzies Health Institute Queensland (MIHQ), Griffith University, Nathan, Queensland, Australia.; Menzies Health Institute Queensland (MIHQ), Griffith University, Nathan, Queensland, Australia.; School of Biomedical Science, Centre for Biomedical Technologies, Faculty of Health, Queensland University of Technology, Brisbane, Queensland, Australia.; Department of Medical Laboratory Sciences, Faculty of Health Sciences, The Open University of Sri Lanka, Nugegoda, Sri Lanka., Tang KD; School of Biomedical Science, Centre for Biomedical Technologies, Faculty of Health, Queensland University of Technology, Brisbane, Queensland, Australia.; EDA School of Biological Sciences and Biotechnology and Nankai International Advanced Research Institute (Shenzhen Futian), Nankai University, Tianjin, People's Republic of China., Barrero RA; eResearch, Academic Division, Queensland University of Technology, Brisbane, Queensland, Australia., Hartel G; Statistics Unit, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia., Liu Z; Department of Otolaryngology, Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia.; Faculty of Medicine, The University of Queensland, Herston, Queensland, Australia., Ladwa R; Faculty of Medicine, The University of Queensland, Herston, Queensland, Australia.; Department of Cancer Care Services, Princess Alexandra Hospital, Woolloongabba, Queensland, Australia., Langton-Lockton J; Metro-North Sexual Health and HIV Service, Brisbane, Queensland, Australia., Frazer I; Faculty of Medicine, The University of Queensland, Herston, Queensland, Australia., Kenny L; Faculty of Medicine, The University of Queensland, Herston, Queensland, Australia.; Department of Cancer Care Services, Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia., Vasani S; Saliva and Liquid Biopsy Translational Laboratory, Griffith Institute for Drug Discovery (GRIDD) and Menzies Health Institute Queensland (MIHQ), Griffith University, Nathan, Queensland, Australia.; Department of Otolaryngology, Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia.; Faculty of Medicine, The University of Queensland, Herston, Queensland, Australia., Punyadeera C; Saliva and Liquid Biopsy Translational Laboratory, Griffith Institute for Drug Discovery (GRIDD) and Menzies Health Institute Queensland (MIHQ), Griffith University, Nathan, Queensland, Australia.; Menzies Health Institute Queensland (MIHQ), Griffith University, Nathan, Queensland, Australia.
Jazyk: angličtina
Zdroj: Cancer medicine [Cancer Med] 2023 Jul; Vol. 12 (14), pp. 15128-15140. Date of Electronic Publication: 2023 Jun 06.
DOI: 10.1002/cam4.6185
Abstrakt: Background: Despite the rising incidence, particularly of the human papillomavirus (HPV)-associated fraction of oropharyngeal cancer (OPC), there are no early detection methods for OPC. Considering the close association between saliva and head and neck cancers, this study was designed to investigate salivary micro RNA (miRNAs) associated with OPC, especially focusing on HPV-positive OPC.
Methods: Saliva was collected from OPC patients at diagnosis and patients were clinically followed up ≤5 years. Salivary small RNA isolated from HPV-positive OPC patients (N = 6), and HPV-positive (N = 4) and negative controls (N = 6) were analysed by next-generation sequencing to identify dysregulated miRNAs. Discovered miRNAs were validated by quantitative PCR using two different assays in a separate cohort of patients (OPC = 91, controls = 92). The relative expression was calculated considering SNORD-96A as the normalizer. Candidate miRNAs with diagnostic and prognostic potential were evaluated by generalized logistic regression.
Results: A panel consisting of nine miRNAs was identified to have the best diagnostic performance to discriminate HPV-positive OPC from HPV-positive controls (AUC- validation-1 = 94.8%, validation-2 = 98%). Further, a panel consisting of six miRNAs were identified to discriminate OPC from controls regardless of the HPV status (AUC- validation-1 = 77.2%, validation-2 = 86.7%). In addition, the downregulation of hsa-miR-7-5p was significantly associated with poor overall survival of OPC patients (HR = 0.638). A panel consisting of nine miRNAs were identified for the prediction of the overall survival of the OPC patients (log-rank test-p = 0.0008).
Conclusion: This study highlights that salivary miRNAs can play an essential role in the detection and prognostication of OPC.
(© 2023 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje